Cargando…
Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
Fifty-two patients with epithelial ovarian cancer were treated with yttrium-90-labelled monoclonal antibody HMFG1 administered intraperitoneally following conventional surgery and chemotherapy as part of an extended phase I-II trial. The treatment was well tolerated and the only significant toxicity...
Autores principales: | Hird, V., Maraveyas, A., Snook, D., Dhokia, B., Soutter, W. P., Meares, C., Stewart, J. S., Mason, P., Lambert, H. E., Epenetos, A. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968585/ https://www.ncbi.nlm.nih.gov/pubmed/8347497 |
Ejemplares similares
-
Tumour localisation with a radioactively labelled reshaped human monoclonal antibody.
por: Hird, V., et al.
Publicado: (1991) -
Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model.
por: Rowlinson-Busza, G., et al.
Publicado: (1995) -
Monoclonal antibodies for imaging and therapy.
por: Epenetos, A. A., et al.
Publicado: (1989) -
A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.
por: Dhokia, B., et al.
Publicado: (1986) -
A low pH enzyme linked immunoassay using two monoclonal antibodies for the serological detection and monitoring of breast cancer.
por: Dhokia, B., et al.
Publicado: (1986)